Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American … – MarketWatch (press release)

Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American
MarketWatch (press release)
5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston. "In addition to a reduced rate of serious bacterial infections, the phase III study data suggest potentially useful attributes of HyQ, such as the possibility

and more »

View full post on asthma – Google News